Key points:
- Lawmakers in thirteen states are working on changing the rules about psychedelics, which are substances that can alter the mind.
- This is happening at the same time as some federal decisions and actions by President Biden and the VA related to these substances.
- Some of the proposals aim to make psychedelic treatments available for people with mental health or medical conditions, especially veterans and first responders. Read from source...

- The title is misleading and does not accurately reflect the content of the article. It implies that psychedelics reform policies are advancing in 13 states on both federal and local levels, but only four states are mentioned (Arizona, Wisconsin, New Hampshire, and New York). Additionally, the article focuses mostly on psilocybin-assisted therapy and neglects other forms of psychedelics.
- The author uses vague terms such as "therapeutic purposes" and "planta-based therapies" without defining them or providing any context. This creates confusion for readers who are not familiar with the topic and makes it difficult to understand the scope and implications of the proposed policies.
- The article relies heavily on external sources, such as Marijuana Moment and Benzinga Staff Writer Lara Goldstein, without acknowledging their biases or potential conflicts of interest. This undermines the credibility of the article and raises questions about its objectivity.
- The article does not provide any data or evidence to support the claims made in the introduction, such as the speed at which state-level psychedelics policy reform is moving throughout the country. This makes it impossible for readers to verify the accuracy of the information presented or assess the impact of these policies on society.
- The article fails to address any potential risks or drawbacks associated with the legalization and regulation of psilocybin-assisted therapy, such as safety concerns, regulatory challenges, or ethical issues. This creates a one-sided perspective that does not consider the broader implications of these policies for individuals, communities, and society as a whole.

There are several factors to consider when making investments in the psychedelics industry, including the potential for policy changes, market demand, competition, regulatory hurdles, and scientific evidence. Some of the key players in this emerging sector include companies involved in research, development, production, and distribution of psychedelic drugs and therapies, as well as those providing related services and technologies.

One potential investment strategy is to focus on companies with strong scientific and clinical data supporting their products and platforms, as this can help mitigate some of the regulatory risks associated with this industry. Additionally, it may be prudent to diversify across different psychedelics and indications, as well as geographic markets, in order to reduce exposure to any single market or product failure.

Some examples of companies that could potentially benefit from the growing interest and momentum in the psychedelics reform movement include:

- Compass Pathways (CMPS): A clinical-stage drug development company focused on creating a new model of psilocybin therapy for mental health disorders, with phase 2b trial results expected soon. The company has partnered with leading research institutions and has received Breakthrough Therapy and Fast Track designations from the FDA for its lead product candidate, COMP360.
- MindMed (MNMD): A neuroscience and psychedelic drug development company that is developing a pipeline of novel therapies and products based on natural psychedelics and synthetic molecules, with a focus on treating mental health and substance use disorders, as well as pain and other indications. The company has multiple programs in clinical trials and has also entered into strategic partnerships and collaborations with various industry stakeholders.
- Cybin (CYBN): A biopharmaceutical company developing a proprietary platform for psychedelic drug discovery and development, using advanced molecular engineering techniques to design novel compounds that target specific brain receptors and pathways associated with various therapeutic applications. The company has an extensive intellectual property portfolio and is currently advancing several preclinical candidates toward clinical trials.
- Field Trip Health (FTRP): A mental health care company offering ketamine-assisted therapy, psychedelic-enhanced therapy, and other holistic treatment options for a range of conditions, including depression, anxiety, PTSD, and addiction. The company has opened several clinics across North America and is also conducting its own research on the efficacy and safety of its treatments.
- Seelos Therapeutics (SELOS): A biopharmaceutical company focused on developing and commercializing novel therap